Cell binding of UC-961 and VLS-101
| ROR1+ cell line . | Cancer type . | UC-961 EC50, ng/mL . | VLS-101 EC50, ng/mL . | 
|---|---|---|---|
| JeKo-1 | MCL | 17.0 | 13.6 | 
| Patient sample #1 | CLL | 14.2 | 17.4 | 
| Patient sample #2 | CLL | 16.8 | 18.9 | 
| Patient sample #3 | CLL | 13.3 | 14.4 | 
| ROR1+ cell line . | Cancer type . | UC-961 EC50, ng/mL . | VLS-101 EC50, ng/mL . | 
|---|---|---|---|
| JeKo-1 | MCL | 17.0 | 13.6 | 
| Patient sample #1 | CLL | 14.2 | 17.4 | 
| Patient sample #2 | CLL | 16.8 | 18.9 | 
| Patient sample #3 | CLL | 13.3 | 14.4 | 
Cultured ROR1+ JeKo-1 cell line and 3 ROR1+ primary CLL patient samples were harvested and incubated at 4°C with UC-961 or VLS-101 followed by a fluorophore-conjugated secondary antibody and viability staining, and then analyzed by flow cytometry. The table provides the EC50 of the viable cell population. Comparable data were obtained from at least 3 independent experiments.